Lumiera Health Beheer

Beheer criteriumcontroles 0/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

Have Insiders Been Buying Lumiera Health Inc. (CVE:NHP) Shares?

Feb 16

CEO

Lumiera Health heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Marie Belanger	Independent Director	4.1yrs	geen gegevens	0.088% CA$ 750.0
Louis Doyle	Independent Director	2.9yrs	geen gegevens	0.25% CA$ 2.1k
André Rancourt	Director	less than a year	CA$11.67k	10.09% CA$ 85.8k
Jacqueline Khayat	Independent Director	2.7yrs	CA$5.97k	0.082% CA$ 701.0
Shawn Moniz	Independent Director	less than a year	geen gegevens	geen gegevens
Kevin Cole	Independent Chairman	4.1yrs	geen gegevens	0.33% CA$ 2.8k

2.8yrs

Gemiddelde duur

Ervaren bestuur: NHP.H's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Lumiera Health Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Lumiera Health Inc., Annual General Meeting, Nov 14, 2023

Lumiera Health Inc. Announces Board Resignations

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Lumiera Health Appoints Jacqueline Khayat to Board of Directors

Recent updates

Lumiera Health's Listing to Transfer to NEX from Tier 2 Effective at the Opening on April 19, 2024

Lumiera Health Inc., Annual General Meeting, Nov 14, 2023

Lumiera Health Inc. Announces Board Resignations

Less than half of directors are independent

Lumiera Health Inc. announced that it expects to receive CAD 0.6 million in funding

Less than half of directors are independent

Third quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2021)

Lumiera Health Inc. to Report Q3, 2022 Results on Oct 28, 2022

Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.009 profit in 2Q 2021)

Lumiera Health Inc. to Report Q2, 2022 Results on Jul 29, 2022

Lumiera Health Inc. Files New NPN Application with Health Canada to Extend Awaye Pain Relief Product Line

Less than half of directors are independent

Lumiera Health Appoints Jacqueline Khayat to Board of Directors

Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)

Lumiera Health Begins Sales of Awaye Pain Relief Cream on Amazon Marketplace

Lumiera Health Inc. announced that it expects to receive CAD 0.9 million in funding

Second quarter 2021 earnings released: EPS CA$0.009 (vs CA$0.006 loss in 2Q 2020)

Lumiera Health Inc. announced that it expects to receive CAD 1.3 million in funding

First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.005 loss in 1Q 2020)

Lumiera Health Inc. Announces Executive Changes

Full year 2020 earnings released: CA$0.029 loss per share (vs CA$0.027 loss in FY 2019)

Have Insiders Been Buying Lumiera Health Inc. (CVE:NHP) Shares?

Lumiera Health Inc. Announces Management Changes

Lumiera Health Inc. Announces the Commercial Launch of Bazzzics a Natural, Over-The-Counter Product Lines, Targeting Sleep Disorders and Anxiety

Insider recently bought CA$295k worth of stock

Third quarter earnings released

Mondias Natural Products Inc. (TSXV:NHP) completed the acquisition of Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) and certain minority shareholders.

Mondias Natural Products Inc. announced that it expects to receive CAD 1 million in funding

Mondias Natural Products Inc Announces Executive Changes

Mondias Natural Products Inc. (TSXV:NHP) signed a binding letter of intent to acquire Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) for CAD 1.4 million.

CEO

Bestuursleden

Gemiddelde duur